Business Wire

ADVA

5.5.2022 09:02:06 CEST | Business Wire | Press release

Share
ADVA plays key role in new QKD projects to accelerate commercial rollout

ADVA (FSE: ADV) today announced that it’s playing a key role in three research and development (R&D) projects building future-proof secure communication networks based on quantum key distribution (QKD). Funded by Germany’s Federal Ministry of Education and Research (BMBF), the initiatives aim to address the significant cybersecurity threat posed by quantum hacking and create the next generation of quantum-safe transport infrastructure with technology made in Germany. In cooperation with other consortium partners, ADVA will accelerate the commercial adoption of QKD technology by making it deployable at scale, robust and easy to integrate.

“The looming threat of large quantum computers puts our most sensitive data at risk. There’s also the immediate danger of cybercriminals harvesting encrypted information now so they can decrypt it when quantum computers become accessible. This is why the switch to quantum-safe encryption is essential for the long-term security of critical data. QKD is based on quantum technology and protects the key exchange between communication endpoints. Even if there is future progress in decryption algorithms and computational capabilities, either classical or quantum, an adversary cannot intercept the keys,” said Michael Roth, GM at Network Security, ADVA. “We understand the requirements of both the quantum and the communication world. By lending our technology and know-how, we’re bridging the gap between them. The BMBF-funded initiatives we’re involved in will make QKD usable for commercial and government customers. Together with our partners, we’re moving this technology to the next level for robust, seamless deployment at scale in today’s optical networks.”

Each of the three projects involves a consortium of industry and research partners with leading expertise in quantum technologies, cryptography, optical communication, and network operation. Coordinated by Deutsche Telekom, the DemoQuanDT project will demonstrate secure quantum key exchange over a fiber optic link between Berlin and Bonn and investigate key management in a multi-vendor environment. Led by Infosim, the QuNet+ML project will research methods for optimizing quantum key distribution in large-scale networks using machine learning. And finally, the DE-QOR project led by ADVA will develop compact and cost-effective continuous-variable QKD (CV-QKD) technology compatible with existing metro and long-distance fiber infrastructure.

“QKD offers a way to achieve true long-term network security today. In just a few years, we’re likely to see current public key cryptosystems rendered obsolete by malicious actors with quantum computers, whether that’s criminal organizations seeking profit or state-sponsored actors aiming to infiltrate critical national infrastructure. It’s therefore crucial that we harness quantum technology quickly in order to stay ahead in the cybersecurity race. Our involvement in these latest BMBF projects is testament to ADVA’s role as a leader in this vital R&D space,” commented Helmut Griesser, director of advanced technology at ADVA. “From day one, our ConnectGuard encryption technology has been at the forefront of quantum-safe communication by offering an open, standards-based interface to external QKD systems. Leveraging our expertise in coherent transmission, digital signal processing and cryptography, we’re now working towards our own CV-QKD solution to give customers more choice.”


About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .

Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com

Social Media:

https://www.facebook.com/ADVAOpticalNetworking

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release

Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me

BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release

Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release

Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely

MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release

The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav

New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release

Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye